Xiang HY, Xiang XY, Ten TB, Ding X, Liu YW, Luo CH. Clinical value of chemiluminescence method for detection of antinuclear antibody profiles. World J Clin Cases 2023; 11(28): 6688-6697 [PMID: 37901001 DOI: 10.12998/wjcc.v11.i28.6688]
Corresponding Author of This Article
Chun-Hua Luo, MD, Attending Doctor, Medical Laboratory Science, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, No. 183 Yiling Avenue, Yichang 443003, Hubei Province, China. douxia833@126.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hui-Yao Xiang, Xi-Ying Xiang, Ting-Bo Ten, Xie Ding, Yu-Wen Liu, Chun-Hua Luo, Medical Laboratory Science, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang 443003, Hubei Province, China
Author contributions: Xiang HY and Xiang XY proposed the concept of this study; Ten TB and Ding X contributed to data collection; Liu YW and Luo CH contributed to formal analysis; Luo CH and Xiang HY participated in the investigation; Xiang XY and Ten TB have contributed to these methods; Xiang HY, Xiang XY, Luo CH guide the research; Ding X validated this study; Xiang HY and Luo CH contributed to the visualization of this study; Xiang HY and Xiang XY have prepared the first draft; Xiang HY, Xiang XY, Ten TB, Ding X, Liu YW, and Luo CH reviewed and edited the manuscript.
Institutional review board statement: This research has been approved ethically by Yichang Central People's Hospital (The First Clinical School of China Three Gorges University, China).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors declare that there are no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Hua Luo, MD, Attending Doctor, Medical Laboratory Science, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, No. 183 Yiling Avenue, Yichang 443003, Hubei Province, China. douxia833@126.com
Received: July 6, 2023 Peer-review started: July 6, 2023 First decision: July 27, 2023 Revised: July 28, 2023 Accepted: August 31, 2023 Article in press: August 31, 2023 Published online: October 6, 2023 Processing time: 81 Days and 2.3 Hours
Core Tip
Core Tip: Antinuclear antibodies (ANAs) are important biomarkers for diagnosing autoimmune diseases, with systemic lupus erythematosus (SLE) being one of the most well-known. This study aimed to compare the performance of two commonly used ANA detection methods, chemiluminescence assay (CLIA) and line immunoassay, in patients with autoimmune diseases. The findings demonstrated that for ANAs, particularly those associated with SLE, both techniques had equivalent detection rates and diagnostic precision. Additionally, a diagnostic model for SLE that uses CLIA-detected antibodies has been developed and shown to have better diagnostic accuracy than individual antibodies. Specifically, a combination of anti-dsDNA antibodies and anti-Ro60 antibodies detected by CLIA provided an effective strategy for diagnosing SLE. These results imply that an adequate diagnosis of SLE may benefit from a diagnostic model based on CLIA-detected antibodies, ultimately resulting in more efficient management and treatment of this autoimmune disease.
